Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LCP-Tacro vs Generic Tacrolimus in African American Renal Transplant Patients
NCT01962922Phase 3Completed
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Jul 2015
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Envarsus XR in kidney transplant rejection (2 arms), sponsored by Veloxis Pharmaceuticals. Primary endpoints: Area Under the Curve from 0 to 24 hours, Maximum Plasma Concentration at Day 21 and 1 more. Started Nov 2013; status: completed.
02
Drugs
Envarsus XR
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01962922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01962922.